Whitehawk Therapeutics, Inc. (WHWK) AI Stock Analysis
WHWK AI stock analysis summary
AI ResearchWhitehawk Therapeutics, Inc. (WHWK) is a clinical-stage oncology therapeutics company focused on developing antibody drug conjugate portfolios for cancer treatment. Over the trailing twelve months ended June 30, 2026, the company generated $0 in revenue and posted a net income of -$20.6M in FY2025. It maintains a strong liquidity profile with $190.0M in cash and short-term investments as of June 30, 2026.
- Market cap
- $164.8M
- Revenue (TTM)
- $0
- P/E
- — fwd 2.7x
- 1Y return
- 10.7% S&P 500 16.8%
- Avg. target
- $7.71 166.9% vs last close
Bull case
- Whitehawk holds $190.0M in cash and short-term investments with a current ratio of 17.38 as of June 30, 2026.
- Wall Street analysts target a mean price of $7.71, implying a 166.9% upside from the last close of $2.89.
- The stock's forward P/E of 2.7x trades well below the US-listed Healthcare peer median of 17.3x.
Bear case
- Trailing twelve months revenue dropped to $0 after quarterly revenue fell 100.0% year-over-year as of June 30, 2026.
- The company recorded negative cash generation in FY2025, including free cash flow of -$98.0M and operating cash flow of -$97.4M.
- Shareholders endured heavy dilution, reflected by a 5-year share count change of 296.8%.
What Whitehawk Therapeutics does
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey. The organization employs 32 people.
Growth and profitability
Whitehawk Therapeutics grew revenue from $1.1M in FY2021 to $15.2M in FY2022, $24.4M in FY2023, and $26.0M in FY2024, before revenue fell 72.5% to $7.1M in FY2025. Its 5-year revenue CAGR from FY2020 to FY2025 was -13.3%. In FY2025, gross margin reached 89.4%, operating margin was -1601.1%, and net margin was -288.3%, yielding net income of -$20.6M and an EPS of -$1.71. For the trailing twelve months ended June 30, 2026, revenue stood at $0 following a 100.0% year-over-year quarterly revenue decline, while EPS TTM was -$1.14.
Balance sheet and cash flow
As of June 30, 2026, Whitehawk Therapeutics held $190.0M in cash and short-term investments, with total assets of $194.0M and shareholders' equity of $182.9M. The company reported a current ratio of 17.38. In FY2025, operating cash flow was -$97.4M and free cash flow was -$98.0M, driven by $91.0M in R&D expense. Cash was also deployed for capital expenditures of $552,000, while the 5-year share count change was 296.8%.
Valuation and performance
Whitehawk Therapeutics has a market cap of $164.8M and an enterprise value of $73.2M. The stock trades at a forward P/E of 2.7x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 30.0x versus the peer median of 4.1x, and EV/EBITDA is 9.4x compared to the peer median of 12.0x. The stock gained 10.7% over the past year, trailing the S&P 500 (SPY) return of 16.8%, and its 5-year return of -89.4% lagged SPY's 83.0% advance.
What analysts expect
Wall Street analyst ratings comprise 5 Strong Buy, 1 Buy, and 3 Hold recommendations. The mean price target is $7.71, representing a 166.9% increase from the last close of $2.89. For the current fiscal year ending December 31, 2026, analysts estimate EPS of -$0.97 and revenue of $0. For the next fiscal year, 4 analysts project revenue of $0 and EPS of -$0.99. Whitehawk beat EPS estimates in 3 of the last 4 quarters, with its next earnings date on November 5, 2026.
Key risks and what to watch
- Whitehawk's top-line trend is negative, reflecting a 5-year revenue CAGR of -13.3% between FY2020 and FY2025.
- Returns on capital are deeply negative, including a return on equity of -45.0% and return on assets of -28.7%.
- High research spending of $91.0M in FY2025 continues to weigh on net results, which stood at -$20.6M.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this WHWK AI stock analysis
This page is an AI-written research summary of Whitehawk Therapeutics, Inc. (WHWK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: WHWK income statement, WHWK balance sheet, WHWK key metrics, WHWK analyst forecast, WHWK chart. See the WHWK stock overview for the latest quote and news.
WHWK AI stock analysis FAQ
What is Whitehawk Therapeutics' ticker and where does it trade?
Whitehawk Therapeutics trades on the NASDAQ exchange under the ticker symbol WHWK.
What is the analyst price target for WHWK?
The mean analyst price target is $7.71, which sits 166.9% above the last close of $2.89.
Does Whitehawk Therapeutics pay a dividend?
Whitehawk Therapeutics does not pay a dividend.
How much cash does Whitehawk Therapeutics have?
As of June 30, 2026, Whitehawk Therapeutics reported $190.0M in cash and short-term investments.
When is the next earnings release for WHWK?
The company's next earnings date is scheduled for November 5, 2026.